FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET
Evidence for efficacy is based on the results from the CABINET study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1642 results
Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies
EMA Recommends Extension of Indications for Glofitamab
New indication concerns the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified who are ineligible for autologous stem cell transplant
Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In the EU
An up-to-date projection of cancer mortality patterns in the European Union
Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC
Findings from the SUNNIFORECAST study
Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for Treatment of Patients with Metastatic NSCLC
Findings from the 3475A-D77 study
FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)
Evidence for efficacy is based on the results from the KEYNOTE-811 study
EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab
It is intended for the treatment of patients with relapsed and refractory multiple myeloma
Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC
Findings from the KEYNOTE-921 study
Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer
Final survival results from the PENELOPE-B study
Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients with Intermediate-Risk Cervical Cancer
Findings from a cohort study conducted at Commission on Cancer accredited centres across the US
FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour
Evidence for efficacy is based on the results from the MOTION study